Freeline Therapeutics (FRLN) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free FRLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 24, 2024 | globenewswire.comFreeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingFebruary 25, 2024 | benzinga.comFreeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | globenewswire.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 19, 2024 | marketbeat.comTrading was temporarily halted for "FRLN" at 07:02 PM with a stated reason of "News pending."February 13, 2024 | finanznachrichten.deFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comFreeline Shareholders Approve Acquisition by SynconaFebruary 9, 2024 | uk.finance.yahoo.comFreeline Therapeutics Holdings plc (FRLN)December 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLNNovember 30, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)November 29, 2023 | businesswire.comFREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline ...November 23, 2023 | finance.yahoo.comFreeline (FRLN) Shares Rise on Merger Agreement With SynconaNovember 22, 2023 | finanznachrichten.deSyncona Limited to Acquire Freeline TherapeuticsNovember 22, 2023 | tmcnet.comFRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to ShareholdersNovember 22, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 07:11 AM with a stated reason of "News pending."November 18, 2023 | seekingalpha.comFRLN Freeline Therapeutics Holdings plcNovember 6, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 10:11 AM with a stated reason of "LULD pause." Trading set to resume at 10:11 AM. November 5, 2023 | morningstar.comFreeline Therapeutics Holdings PLC ADR FRLNOctober 28, 2023 | markets.businessinsider.comFreeline Therapeutics: Promising Initial Efficacy Data and Potential for High Revenues Justify Buy RatingOctober 25, 2023 | finance.yahoo.comFreeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressOctober 19, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn SituationOctober 18, 2023 | markets.businessinsider.comWhere Freeline Therapeutics Stands With AnalystsOctober 16, 2023 | finance.yahoo.comFreeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressOctober 6, 2023 | marketwatch.comFreeline Therapeutics ADRs Rise 14% Following Positive Trial Data on FLT201October 5, 2023 | markets.businessinsider.comPromising Gaucher Disease Trial Results and Potential Parkinson’s Disease Impact Bolster Analyst’s Buy Rating for Freeline Therapeutics HoldingsOctober 4, 2023 | benzinga.comWhy Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today?October 4, 2023 | markets.businessinsider.comFreeline Reports Positive Data From First Cohort Of Phase 1/2 GALILEO-1 Trial Of FLT201October 4, 2023 | finance.yahoo.comFreeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseAugust 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Freeline Therapeutics Holdings (FRLN)August 17, 2023 | finance.yahoo.comFreeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call TranscriptAugust 16, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Freeline TherapeuticsAugust 16, 2023 | finance.yahoo.comQ2 2023 Freeline Therapeutics Holdings PLC Earnings CallAugust 15, 2023 | seekingalpha.comFreeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62MAugust 15, 2023 | finanznachrichten.deFreeline Therapeutics Holdings plc: Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 15, 2023 | finance.yahoo.comFreeline Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 14, 2023 | benzinga.comFreeline Therapeutics's Earnings: A PreviewAugust 8, 2023 | finance.yahoo.comFreeline Therapeutics to Host Second Quarter 2023 Financial Results CallJuly 25, 2023 | finance.yahoo.comFreeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseJuly 20, 2023 | thestreet.comFreeline Therapeutics Holdings plcJuly 14, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 02:07 PM with a stated reason of "LULD pause." Trading set to resume at 02:07 PM. July 13, 2023 | benzinga.comFreeline Therapeutics Holdings Shares Halted On Circuit Breaker To The Upside, Up 53.1%July 13, 2023 | finance.yahoo.comEstimating The Fair Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 10:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 10:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 10:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 10:07 AM with a stated reason of "LULD pause." Trading set to resume at 10:07 AM. July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 09:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "FRLN" at 09:07 AM with a stated reason of "LULD pause."June 26, 2023 | tmcnet.comFreeline Announces First Patient Dosed with Its NovelJune 26, 2023 | finance.yahoo.comFreeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease Get Freeline Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FRLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge FRLN Media Mentions By Week FRLN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FRLN News Sentiment▼0.000.55▲Average Medical News Sentiment FRLN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FRLN Articles This Week▼01▲FRLN Articles Average Week Get Freeline Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FRLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LianBio News PHAXIAM Therapeutics News DURECT News Lipocine News Inspira Technologies Oxy B.H.N. News Evogene News SeaStar Medical News Enlivex Therapeutics News CareCloud News Spectral AI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FRLN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
